Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab vs Tocilizumab in Refractory Takayasu Arteritis
NCT04564001Phase 2Unknown
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2020
- Primary completion
- Feb 2021
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
01
Overview
A Phase 2 trial of infliximab, tocilizumab in Takayasu arteritis (TAK), sponsored by Assistance publique - Hôpitaux de Paris. Status: unknown.
02
Drugs
infliximabtocilizumab
03
Conditions
Takayasu arteritis (TAK)
Beyond the preview
Go deeper on NCT04564001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04564001.